Table 1 Performance characteristics of the included studies 2012–2020
From: Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review
Authors | No. Part | Biomarkers | Current Status | Test platform | Sample type | Sensitivity | Specificity | PPV | NPV | AUC | Mean TAT |
|---|---|---|---|---|---|---|---|---|---|---|---|
Farzanehpour et al, 2019 [2] | 72 | miRNA (miR-9) | Not validated | RT-qPCR | Tissue | 64.7% | 76.4% | – | – | 0.71 | ≤ 5 h. |
Farzanehpour et al. 2019 [2] | 72 | miRNA (miR-9) | Not validated | RT-qPCR | Serum | 52.9% | 94.4% | – | – | 0.85 | ≤ 5 h. |
Park et al., 2017 [11] | 102 | miRNA (miR-9) | Not validated | RT-qPCR | Tissue | 67.3% | 80% | 77.7% | 70.2% | 0.76 | ≤ 5 h. |
Wentzensen et al, 2012 [12] | 673 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 85.5% | 59.4% | 48.4%% | 90.2%% | – | ≤24 h |
Zhu et al, 2019 [13] | 300 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 98.2% | 82.5% | 55.2% | 99.5%% | 0.90 | ≤24 h |
Areán-Cun., et al, 2018 [14] | 1945 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 98% | 39% | 44.8% | 97.5% | – | ≤24 h |
Wentzensen et al, 2015 [15] | 1509 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 83.4% | 58.9% | 21% | 96.4% | – | ≤24 h |
Yu et al, 2016 [16] | 231 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 90.9% | 79.5% | 49.2% | 97.6% | 0.85 | ≤24 h |
Tay et al., 2017 [17] | 97 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 92.9% | 76.7% | 88.1% | 86.7% | 0.85 | ≤24 h |
Ebisch et al., 2017 [18] | 462 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 92% | 61% | 52% | 95% | – | ≤24 h |
Hu et al., 2020 [19] | 846 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 86.5% | 62.5% | 28.8% | 96.4% | – | ≤24 h |
Ordi et al., 2014 [20] | 1169 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 90.9% | 72.1% | 63.9% | 93.6% | 0.82 | ≤24 h |
Uijterwaal et al., 2015 [21] | 762 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 68.8% | 72.8% | 25.2% | 94.6% | – | ≤24 h |
White et al., 2016 [22] | 1346 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 75.4% | 88.3% | 26.6% | 97% | – | ≤24 h |
Schmitz et al., 2018 [23] | 280 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 100% | 90.2% | 92.3% | 100% | – | ≤24 h |
Han et al., 2020 [24] | 468 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 91.5% | 77% | 73.9% | 92.8% | 0.76 | ≤24 h |
Li et al., 2020 [25] | 4070 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 90.9% | 67%. | 16.5% | 99.1% | 0.79 | ≤24 h |
Wang et al., 2020 [26] | 4070 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 91.7% | 63.5% | 29.3% | 97.9% | – | ≤24 h |
El-Zein et al., 2020 [27] | 1649 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 80.7% | 69.4% | 64% | 71.8% | – | ≤24 h |
Wentzensen et al, 2019 [28] | 3225 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 82.8% | 55.7% | 24.3% | 95% | – | ≤24 h |
Ren et al., 2019 [29] | 300 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 50% | 75.3% | 11.1% | 96.1% | 0.78 | ≤24 h |
Bergeron, et al., 2015 [30] | 27,349 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 94.4% | 78.7% | 16.3% | 99.7% | – | ≤24 h |
Polman et al., 2016 [31] | 364 | p16INK4a / ki-67 | Not validated | ICC CINtec PLUS | LBC | 69.2% | 90.4% | 51.9% | 95.1% | – | ≤24 h |
Ren et al., 2019 [29] | 300 | HPV E6/E7 mRNA | Not validated | QuantiVirus ®HPV | LBC | 100% | 44.3% | 10% | 100%% | 0.59 | ≤ 5 h. |
Ren et al, 2018 [32] | 160 | HPV E6/E7 mRNA | Not validated | QuantiVirus®HPV | LBC | 90.3% | 49.6% | 30.1% | 95.5% | 0.75 | ≤ 5 h |
Han et al., 2018 [33] | 6800 | HPV E6/E7 mRNA | Not validated | QuantiVirus ®HPV | LBC | 85.2% | 66.7% | 72.9% | 81% | 0.75 | ≤ 5 h |
Yao et al., 2017 [34] | 404 | HPV E6/E7 mRNA | Not validated | QuantiVirus® HPV | LBC | 89.5% | 49% | 39% | 92.7% | 0.72 | ≤ 5 h |
Zhu et al, 2019 [13] | 300 | HPV E6/E7 mRNA | Not validated | QuantiVirus® HPV | LBC | 87% | 42.7% | 25% | 93.8% | 0.70 | ≤ 5 h |
Bountris et al, 2014 [35] | 740 | HPV E6/E7 mRNA | Not validated | NASBA assay | LBC | 77% | 90.2% | 68.5% | 93.4% | – | ≤ 5 h |
Li et al, 2016 [36] | 186 | HPV E6/E7 mRNA | Not validated | QuantiVirus® HPV | LBC | 65% | 86.7% | 85.9% | 66.7% | 0.76 | ≤ 5 h |
Camus et al, 2018 [37] | 502 | HPV E6/E7 mRNA | Not validated | qRT-PCR | LBC | 90% | 50% | 64% | 83% | 0.80 | ≤ 5 h |
Kong et al, 2020 [38] | 600 | DNA methylation | Not validated | qPCR | LBC | 67.7% | 94.9% | 95.4% | 65.5% | 0.86 | ≤ 5 h |
Dong et al, 2020 [39] | 1997 | DNA methylation | Not validated | qPCR | LBC | 92.9% | 73% | 56.5% | 96.4% | 0.83 | ≤ 5 h |
Schmitz et al, 2018 [23] | 280 | DNA methylation | Not validated | RT-PCR | LBC | 59.7% | 98% | 91.5% | 87.3% | – | ≤ 5 h |
van Leeuwen et al.,2019 [40] | 262 | DNA methylation | Not validated | qPCR | LBC | 68% | 67% | 15% | 96% | – | ≤ 5 h |
De Strooper et al, 2016 [41] | 375 | DNA methylation | Not validated | qPCR | LBC | 70.5% | 67.8% | 35.5% | 90.2% | – | ≤ 5 h |
Chujan et al, 2014 [42] | 94 | DNA methylation | Not validated | qPCR | LBC | 83.3% | 96.8% | 92.6% | 92.5% | – | ≤ 5 h |
Kottaridi et al, 2017 [43] | 151 | DNA methylation | Not validated | qPCR | LBC | 75.7% | 77.5% | 74.7% | 78.5% | 0.81 | ≤ 5 h |
Leeman et al, 2019 [44] | 262 | DNA methylation | Not validated | qPCR | LCB | 77.8% | 69.3% | 36.4% | 98.3% | – | ≤ 5 h |
Chen et al, 2020 [45] | 103 | SCC-Ag | Validated | Elisa | Serum | 80% | 100% | 100% | 82.6% | 0.89 | ≤ 5ihrs |
Zajkowska et al, 2018 [46] | 100 | SCC-Ag | Validated | Elisa | Serum | 78.8% | 74% | 66.7% | 84.1% | 0.79 | ≤ 5 h |
Sidorkiewicz et al., 2019 [5] | 85 | SCC-Ag | Validated | Elisa | Serum | 81.2% | 74% | – | – | 0.79 | ≤ 5 h |
Lubowicka et al,2020 [47] | 89 | SCC-Ag | Validated | Elisa | Serum | 78.6% | 74% | – | – | 0.79 | ≤ 5 h |
Zajkowska et al, 2018 [46] | 85 | M-CSF | Not validated | Elisa | Serum | 72.7% | 86% | 77.4% | 82.7% | 0.79 | ≤ 5 h |
Lubowicka et al, 2020 [47] | 89 | M-CSF | Not validated | Elisa | Serum | 75% | 86% | – | – | 0.81 | ≤ 5 h |
Sidorkiewicz et al., 2019 [5] | 85 | M-CSF | Not validated | Elisa | serum | 69.4% | 86% | – | – | 0.81 | ≤ 5 h |
Ruan et al, 2020 [48] | 68 | M-CSF | Not validated | Elisa | Serum | 87.7% | 64.7% | – | – | 0.75 | ≤ 5 h |
Będkowska et al., 2015 [49] | 110 | M-CSF | Not validated | Elisa | Serum | 68% | 94% | 92% | 75% | 0.86 | ≤ 5 h |
Lawicki et al, 2016 [50] | 100 | VEGF | Not validated | Elisa | Serum | 56% | 96% | 86% | 82% | 0.85 | ≤ 5 h |
Sidorkiewicz et al.,2019 [5] | 85 | VEGF | Not validated | Elisa | Serum | 81.2% | 76% | – | – | 0.86 | ≤ 5 h |
Cheng et al., 2013 [51] | 109 | VEGF | Not validated | Elisa | Serum | 83.3% | 74.6% | – | – | 0.83 | ≤ 5 h |
Urquidi et al, 2012 [52] | 127 | VEGF | Not validated | Elisa | Urine | 83% | 87% | – | – | 0.88 | ≤ 5 h |